STAT+: Pharmalittle: Biogen to slash 1,000 more jobs; key House panel proposes lowering Medicare out-of-pocket drug costs
Rise and shine, everyone, another busy day is on the way. This morning is getting…
Category: Pharmaceuticals
As Alzheimer’s drugs hit the market, the race for early detection blood tests heats up
With the advent of disease-modifying Alzheimer’s drugs, everyone in the world of Alzheimer’s diagnostics is…
STAT+: IQVIA built a health data empire to target drug ads. Now it’s the focus of an FTC lawsuit
The health data giant IQVIA became a dominant force by gobbling up its rivals. Over…
STAT+: Lobbying spending dropped for companies that departed PhRMA
WASHINGTON — The three companies that recently left PhRMA all spent less on lobbying following…
STAT+: Pfizer says most tornado damage at key plant hit warehouse, but finished drugs also impacted
Pfizer says a tornado that ripped through a key manufacturing plant in North Carolina does…
STAT+: Major pharma companies call on their suppliers to reduce carbon footprints
As anxiety mounts over climate change, seven of the world’s largest drugmakers urged dozens of…
STAT+: European regulator will review study data from contract research organization due to ‘serious concerns’
In the latest melee over the safety of prescription medicines, the European Medicines Agency is…
STAT+: Damages from tornado at Pfizer plant could compound challenges of drug shortages
The tornado that struck parts of North Carolina on Wednesday not only damaged the immediate…
STAT+: FTC plans to reverse years of policy statements supporting pharmacy benefit managers
The U.S. Federal Trade Commission is reversing years of prior advocacy in support of pharmacy…
STAT+: Hospitals struggle to make money on CAR-T cancer therapies, but their fortunes may change
WASHINGTON — Hospitals for years have complained that Medicare pays so little for CAR-T cancer…
STAT+: DOJ, FTC primed for more aggressive scrutiny of health care mergers
Health care companies trying to merge can expect tougher policing from the top federal antitrust…
STAT+: House committee probes FDA inspections of pharma plants in China and India
A Congressional committee is demanding the U.S. Food and Drug Administration provide detailed information about…
STAT+: App developer Twill hunts for pharma partner to market its digital depression treatment
In another sign of the business headwinds facing prescription mental health apps, developer Twill will…
STAT+: Bernie Sanders adds three drug shortage policies to pandemic preparedness bill
WASHINGTON — Senate health committee Chair Bernie Sanders added three drug shortage measures to a…
STAT+: At Orexo, a ‘turning point’ for everything but digital health
Most everything is looking up for Orexo, the company reported on its second quarter earnings…
STAT+: Johnson & Johnson sues to stop Medicare negotiation
WASHINGTON — Pharmaceutical giant Johnson & Johnson on Tuesday became the third drugmaker to sue the…
STAT+: Novartis is scolded by U.K. trade group for the third time this year over Entresto marketing
For the third time this year, Novartis has been rebuked by a U.K. trade group…
STAT+: Conservative group opposing PBM reform spends record number on lobbying
WASHINGTON — A conservative group advocating against changing how pharmacy middlemen operate spent more than…
STAT+: Colombian government explores compulsory licensing for an HIV drug
The latest clash over the cost of a prescription medicine is playing out in Colombia,…
STAT+: Pharmalittle: Key Senate panel has a plan for PBMs; Roivant eyes $7 billion sale of a stomach drug
And so, another working week will soon draw to a close. Not a moment too…
STAT+: How a key Senate committee is planning to regulate pharmacy benefit managers
WASHINGTON — A key Senate health care panel has developed a plan to tackle reforms…
FDA approves first over-the-counter birth control pill
In a highly anticipated move, the U.S. Food and Drug Administration approved the first over-the-counter…
There’s a bill well-suited for drug shortage reforms, but Congress isn’t interested
WASHINGTON — Congress is considering a must-pass pandemic preparedness bill that presents a good opportunity…
STAT+: Pharmalittle: EU fines Illumina $475M for closing Grail deal; life-threatening lead poisoning antidote in short supply
Hello, everyone, and how are you this fine, sunny morning? The middle of the week…
.jpg)
STAT+: How to ‘break the logjam’? Economists pitch a plan to curb dire drug shortages
There are alarmingly frequent reports of shortages of vitally needed medicines. From tablets to treat…
STAT+: Pharmalittle: Eisai exec who helped lead Alzheimer’s drug development to retire; Express Scripts adds three Humira biosimilars to preferred formulary
Top of the morning to you, and a fine one it is. Birds are chirping…
STAT+: Pharmalittle: European regulator probes suicidal risks of weight loss drugs; Pfizer reports shortages of penicillin for fighting syphilis
Good morning, everyone, and welcome to another working week. We hope the weekend respite was…
Biden’s NIH nominee is languishing in Congress — alarming public health advocates
WASHINGTON — Sen. Bernie Sanders’ rare move to delay President Biden’s health care nominees has…
STAT+: What to know about this summer’s landmark Wegovy heart health study
At some point this summer, the drugmaker Novo Nordisk will release results from a closely…
STAT+: With some savvy bets, a dynamic duo makes Eli Lilly one of pharma’s biggest success stories
The partnership that would shape Eli Lilly into one of the biggest success stories in…
.jpg)
STAT+: Novo Nordisk bought prescribers over 450,000 meals and snacks to promote drugs like Ozempic
WASHINGTON – Novo Nordisk spent $11 million on meals and travel for thousands of doctors…
STAT+: AstraZeneca shares fall after lung cancer drug underwhelms in trial
LONDON — AstraZeneca said on Monday that a new lung cancer treatment outperformed standard-of-care chemotherapy…
Opinion: Pharma can’t let Big Tech win the race for medical AI
Five years from now, when patients walk into a doctor’s office presenting symptoms of almost…
STAT+: The biotech scorecard for the third quarter: 15 stock-moving events to watch
Here is STAT’s biotech scorecard, our regular ledger of stock-moving biotech events, for the third…
STAT+: Gilead and Teva defeat antitrust lawsuit that claimed prices for HIV medicines were unfairly kept high
In a setback to AIDS activists, a federal court jury on Friday cleared Gilead Sciences…
STAT+: Medicare details the structure of its new drug price negotiation program
WASHINGTON — Medicare on Friday released new details about how its new drug price negotiation…
Listen: Novavax’s CEO promises a turnaround & how Lilly roiled the obesity market
Can Novavax finally get it right? What’s a “triple-G” drug? And is Novo Nordisk losing…
STAT+: Former Pfizer statistician is charged with insider trading over Paxlovid clinical trial results
A former Pfizer statistician on Thursday was charged by U.S. authorities with insider trading for…
STAT+: Drug wholesaler owner indicted for role in diverting Gilead and J&J HIV medicines
The owner of a pharmaceutical wholesaler has been indicted for his alleged role in distributing…
STAT+: Trump demands the U.S. pay no more for drugs than other countries … again
WASHINGTON — Former President Trump is back to campaigning for tying Medicare drug prices to…
Gates Foundation to launch trial of long-awaited new tuberculosis vaccine candidate
The Gates Foundation said Wednesday it plans to launch a long-awaited trial to test what,…
Opinion: Listen: Cancer drug shortages should be causing more outrage
Drug shortages are a growing problem in the U.S., and a shortage of livesaving cancer…
STAT+: ‘It’s like Groundhog Day’: The cancer drug shortage isn’t new — and neither are the solutions
A young girl, maybe 5 or 6 years old, had come into Yoram Unguru’s clinic…
STAT+: FDA issues warning to wholesaler sued by Gilead and J&J for distributing counterfeit medicines
A year after two major drugmakers sued a wholesaler for its alleged role in distributing…
STAT+: After late start, Eli Lilly starts pulling ahead in race for the $30 billion weight loss market
SAN DIEGO — It was Novo Nordisk’s Ozempic and Wegovy that set off a new…
Opinion: A seemingly small semantic issue is a major roadblock to develop treatments for rare diseases
Finding a new medicine is never easy. But developing treatments for patients with rare diseases…
STAT+: With Wegovy and Ozempic’s success, can device makers keep up in the race to treat obesity?
The makers of minimally invasive surgical devices seemed poised to capture a wide swath of…
STAT+: Fatty liver disease was alleviated by Lilly’s ‘triple-G’ obesity drug in small study
SAN DIEGO — An experimental obesity drug from Eli Lilly significantly reduced liver fat in…
Ozempic 3.0? Lilly’s ‘triple-G’ drug shows biggest weight loss yet in mid-stage trial
SAN DIEGO — Ozempic and Wegovy became weight loss sensations by targeting a single hormone,…
STAT+: STAT-Harris Poll: Nearly half of U.S. adults would spend $100 a month for Ozempic, other weight-loss drugs
Almost half of Americans would be willing to spend up to $100 a month for…